Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Perinatol ; 37(4): 349-354, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-28005062

RESUMO

OBJECTIVE: Delivery room management interventions have been successfully implemented via collaborative quality improvement (QI) projects. However, it is unknown whether these successes translate to reductions in neonatal morbidity and mortality. STUDY DESIGN: This was a prospective pre-post intervention study of three nonrandomized hospital groups within the California Perinatal Quality Care Collaborative. A collaborative QI model (Collaborative QI) was compared with a single-site QI model (NICU QI) and a non-participant population when implementing evidence-based delivery room practices. The intervention period was between June 2011 and May 2012. Infants born with gestational age between 22 weeks 0 days and 29 weeks 6 days and birth weight ⩽1500 g were included. Outcomes were mortality and select morbidities (bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), retinopathy of prematurity (ROP) and necrotizing enterocolitis (NEC)). Outcomes were compared between the baseline (January 2010 to May 2011) and post-intervention period (June 2012 to May 2013) within each comparison group. RESULTS: Ninety-five hospitals were included with 4222 infants in the baseline period and 4186 infants in the post-intervention period. The Collaborative QI group had significantly reduced odds of developing BPD post-intervention (odds ratio (OR) 0.8, 95% confidence interval (CI) 0.65 to 0.99) or composite BPD-death (OR 0.83, 95% CI 0.69 to 1.00). In both the Collaborative QI and non-participants there were also reductions in IVH, severe IVH, composite severe IVH-death, severe ROP and composite severe ROP-death. CONCLUSION: Hospitals dedicated to improving delivery room practices can impact neonatal outcomes.


Assuntos
Salas de Parto/organização & administração , Mortalidade Infantil , Lactente Extremamente Prematuro , Melhoria de Qualidade , Peso ao Nascer , Displasia Broncopulmonar/mortalidade , California/epidemiologia , Hemorragia Cerebral/mortalidade , Enterocolite Necrosante/mortalidade , Feminino , Idade Gestacional , Humanos , Lactente , Recém-Nascido , Recém-Nascido de muito Baixo Peso , Masculino , Análise Multivariada , Gravidez , Estudos Prospectivos , Análise de Regressão , Retinopatia da Prematuridade/mortalidade
2.
J Perinatol ; 37(3): 315-320, 2017 03.
Artigo em Inglês | MEDLINE | ID: mdl-27853320

RESUMO

OBJECTIVE: To examine burnout prevalence among California neonatal intensive care units (NICUs) and to test the relation between burnout and healthcare-associated infection (HAI) rates in very low birth weight (VLBW) neonates. STUDY DESIGN: Retrospective observational study of provider perceptions of burnout from 2073 nurse practitioners, physicians, registered nurses and respiratory therapists, using a validated four-item questionnaire based on the Maslach Burnout Inventory. The relation between burnout and HAI rates among VLBW (<1500 g) neonates from each NICU was evaluated using multi-level logistic regression analysis with patient-level factors as fixed effects. RESULTS: We found variable prevalence of burnout across the NICUs surveyed (mean 25.2±10.1%). Healthcare-associated infection rates were 8.3±5.1% during the study period. Highest burnout prevalence was found among nurses, nurse practitioners and respiratory therapists (non-physicians, 28±11% vs 17±19% physicians), day shift workers (30±3% vs 25±4% night shift) and workers with 5 or more years of service (29±2% vs 16±6% in fewer than 3 years group). Overall burnout rates showed no correlation with risk-adjusted rates of HAIs (r=-0.133). Item-level analysis showed positive association between HAIs and perceptions of working too hard (odds ratio 1.15, 95% confidence interval 1.04-1.28). Sensitivity analysis of high-volume NICUs suggested a moderate correlation between burnout prevalence and HAIs (r=0.34). CONCLUSION: Burnout is most prevalent among non-physicians, daytime workers and experienced workers. Perceptions of working too hard associate with increased HAIs in this cohort of VLBW infants, but overall burnout prevalence is not predictive.


Assuntos
Esgotamento Profissional/epidemiologia , Infecção Hospitalar/epidemiologia , Recém-Nascido de muito Baixo Peso , Unidades de Terapia Intensiva Neonatal/estatística & dados numéricos , California/epidemiologia , Estudos Transversais , Feminino , Humanos , Recém-Nascido , Modelos Logísticos , Masculino , Estudos Retrospectivos , Jornada de Trabalho em Turnos , Inquéritos e Questionários
3.
J Perinatol ; 31(5): 311-7, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21273990

RESUMO

OBJECTIVE: To evaluate the impact of integrating a handoff tool into the electronic medical record (EMR) on sign-out accuracy, satisfaction and workflow in a neonatal intensive care unit (NICU). STUDY DESIGN: Prospective surveys of neonatal care providers in an academic children's hospital 1 month before and 6 months following EMR integration of a standalone Microsoft Access neonatal handoff tool. RESULT: Providers perceived sign-out information to be somewhat or very accurate at a rate of 78% with the standalone handoff tool and 91% with the EMR-integrated tool (P < 0.01). Before integration of neonatal sign-out into the EMR, 35% of providers were satisfied with the process of updating sign-out information and 71% were satisfied with the printed sign-out document; following EMR integration, 92% of providers were satisfied with the process of updating sign-out information (P < 0.01) and 98% were satisfied with the printed sign-out document (P<0.01). Neonatal care providers reported spending a median of 11 to 15 min/day updating the standalone sign-out and 16 to 20 min/day updating the EMR-integrated sign-out (P = 0.026). The median percentage of total sign-out preparation time dedicated to transcribing information from the EMR was 25 to 49% before and <25% after EMR integration of the handoff tool (P < 0.01). CONCLUSION: Integration of a NICU-specific handoff tool into an EMR resulted in improvements in perceived sign-out accuracy, provider satisfaction and at least one aspect of workflow.


Assuntos
Serviços de Saúde da Criança , Continuidade da Assistência ao Paciente/normas , Registros Eletrônicos de Saúde/normas , Unidades de Terapia Intensiva Neonatal/normas , Informática Médica/métodos , Atitude do Pessoal de Saúde , Serviços de Saúde da Criança/organização & administração , Serviços de Saúde da Criança/normas , Continuidade da Assistência ao Paciente/organização & administração , Humanos , Lactente , Recém-Nascido , Unidades de Terapia Intensiva Neonatal/organização & administração , Comunicação Interdisciplinar , Corpo Clínico Hospitalar/educação , Corpo Clínico Hospitalar/normas , Estudos Prospectivos , Melhoria de Qualidade , Desenvolvimento de Pessoal , Fluxo de Trabalho
4.
Pediatrics ; 106(1): E8, 2000 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10878177

RESUMO

OBJECTIVE: To determine whether inhaled steroid therapy causes delayed linear growth in children with asthma. DATA SOURCES: Medline (1966-1998), Embase (1980-1998), and Cinahl (1982-1998) databases and bibliographies of included studies were searched for randomized, controlled trials of inhaled steroid therapy in children with asthma that evaluated linear growth. STUDY SELECTION: Studies were included if they met the following criteria: subjects 0 to 18 years of age with the clinical diagnosis of asthma; subjects randomized to inhaled beclomethasone, budesonide, flunisolide, fluticasone, or triamcinolone versus a nonsteroidal inhaled control for a minimum of 3 months; single- or double-blind; and outcome convertible to linear growth velocity. English- and non-English-language trials were included. DATA EXTRACTION: Data were extracted using a priori guidelines. Methodologic quality was assessed independently by both authors. Outcome was extracted as linear growth velocity. RESULTS: Included trials were subgrouped by inhaled steroid. The beclomethasone subgroup, with 4 studies and 450 subjects, showed a decrease in linear growth velocity of 1.51 cm/year (95% confidence interval: 1.15,1.87). The fluticasone subgroup, with 1 study and 183 subjects, showed a decrease in linear growth velocity of.43 cm/year (95% confidence interval:.01,.85). Sensitivity analysis in the beclomethasone subgroup, which evaluated study quality, mode of medication delivery, control medication, and statistical model, showed similar results. CONCLUSIONS: This meta-analysis suggests that moderate doses of beclomethasone and fluticasone in children with mild to moderate asthma cause a decrease in linear growth velocity of 1.51 cm/year and.43 cm/year, respectively. The effects of inhaled steroids when given for >54 weeks, or on final adult height, remain unknown.


Assuntos
Asma/tratamento farmacológico , Asma/fisiopatologia , Estatura/efeitos dos fármacos , Esteroides/administração & dosagem , Esteroides/uso terapêutico , Administração por Inalação , Adolescente , Androstadienos/administração & dosagem , Anti-Inflamatórios/administração & dosagem , Beclometasona/administração & dosagem , Budesonida/administração & dosagem , Criança , Pré-Escolar , Fluocinolona Acetonida/administração & dosagem , Fluocinolona Acetonida/análogos & derivados , Fluticasona , Crescimento/efeitos dos fármacos , Humanos , Lactente , Recém-Nascido , Triancinolona/administração & dosagem
5.
Cochrane Database Syst Rev ; (2): CD001282, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-10796632

RESUMO

BACKGROUND: Inhaled steroids play a central role in the management of childhood asthma. There is concern about their side effects, especially on growth. However asthma may also cause growth retardation. Growth rates are not stable, so randomised controlled parallel group studies are needed to assess the impact of inhaled steroids on growth. This review is confine to one inhaled steroid, beclomethasone, that is known to have significant levels of systemic absorption. OBJECTIVES: To determine whether inhaled beclomethasone cause significant delay in the linear growth of children with asthma. SEARCH STRATEGY: The Cochrane Airways Group asthma register was searched. Bibliographies from included studies, and known reviews were searched for additional citations. Personal contact with colleagues and researchers working in the field of asthma were made to identify potentially relevant trials. SELECTION CRITERIA: Randomized, controlled trials comparing the effects of beclamethasone to non-steroidal medication (placebo or non-steroidal therapy) on the linear growth of children with asthma. DATA COLLECTION AND ANALYSIS: Data related to the clinical outcome "change in growth" were extracted by two reviewers working independently MAIN RESULTS: One hundred and fifty-nine citations were identified by the search strategy and bibliography review. Three studies met the inclusion criteria. All used beclomethasone 200 mcg twice daily delivered by dry powder Diskhaler to treat children with mild-moderate asthma. Study duration was 7-12 months. In all three studies, a significant decrease in linear growth occurred in children treated with beclomethasone compared to those receiving placebo or non-steroidal asthma therapy. The average decrease, calculated through meta-analysis, was -1.54 cm per year (95% CI -1.15, -1.94). REVIEWER'S CONCLUSIONS: In children with mild-moderate asthma, beclomethasone 200 mcg twice daily caused a decrease in linear growth of -1.54 cm per year. These studies lasted a maximum of 54 weeks, so it remains unclear whether the decrease in growth is sustained or whether it reverses with 'catch up' after therapy is discontinued. We are unable to comment on growth effects of other inhaled steroids that have potentially less systemic effects. If inhaled steroids are required to control a child's asthma, we recommend using the minimum dose that effectively controls the child's asthma and closely following growth.


Assuntos
Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Beclometasona/uso terapêutico , Crescimento/efeitos dos fármacos , Fatores Etários , Antiasmáticos/farmacologia , Beclometasona/farmacologia , Criança , Desenvolvimento Infantil/efeitos dos fármacos , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA